Australian Amyloidosis Network Australia it’s been a blast! Brisbane did we maybe save the best till last?! Such impressive enthusiasm and energy for #amyloidosisawareness not least from the legend Pat Neely! Great to see Peter, Simon, Darius, Niri, Nicholas & James. Huge thanks to all.

The "Amyloidosis 2025" meetings have ended. Farewell to Carol Whelan Stathis. Special🙏Prof Yoshi Sekijima VP/President elect @ISA_Amyloidsis for dialling in to our Workshops & for providing recordings. Ur clinical pearls will improve the care of all our ATTRv patients.

A lot in #mmsm at ASCO. JNJ-5322 is likely the greatest innovation we have seen in a few years. Potential to disrupt our approach to immunotherapy even before we figure out the current players. ⁦J&J Innovative Medicine⁩ congratulations to the investigators meetings.asco.org/abstracts-pres…

#ASCO25 Top myeloma abstracts #mmsm 3️⃣ MagnetisMM-6 part 1 ➡️ meetings.asco.org/abstracts-pres… Elranatamab+ daratumumab+ lenalidomide ✅n=34 pts, median age: 75 years (range, 67-83) ✅median follow up: 4.6 months (short) ✅ORR: 92% 🛑G3/4 infections: 20% with one case of G5 candida

#ASCO25 Top myeloma abstracts #mmsm 5️⃣ ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody ➡️ meetings.asco.org/abstracts-pres… ✅n=24 ✅ ORR: 82% at doses ≥50 µg/kg 🛑Will be imp to see how triple class referactory and penta drug referactory (not only exposed) will do

5/ #ASCO25 #MMsm CAR-T: 7507 CARTITUDE-1 (Plasma Cell Pete): One-third of pts alive & disease-free 5 years (!) after CAR-T & no maintenance 👏 Enrolled 2018-2019, median 6 prior LOT: these pts otherwise would have died. Just need to turn 33% to 100%! meetings.asco.org/abstracts-pres…

Ultimate review on Myeloma bone disease! Open access too doi.org/10.1016/j.blre… #mmsm Vincent Rajkumar Rahul Banerjee, MD, FACP @urvishahMD Ben Derman Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Luciano J Costa Robert Z. Orlowski Shaji Kumar Anup Joseph Devasia

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance iStopMM JAMA Oncology #mmsm jamanetwork.com/journals/jamao… Important data coming to support need for new ranges of normal free light chains based on eGFR👇

🚨 #ASCO25 MIDAS is out! If #MMsm MRD- at 10^-5 after quad, ASCT does not deepen responses. If MRD+, tandem ASCT doesn’t help / refused by 15% of pts. We await PFS of course, but this is very helpful! PS I love that NEJM is now calling MRD measurable (not minimal 👎) as well

ALLG's BM12 CAST trial has shown game-changing results, changing 40 years of standard practice in GVHD prophylaxis for stem cell transplants. Presented at EHA2025 by Prof David Curtis & published in NEJM today, read more here: tinyurl.com/4xujd583 #clinicaltrials #EHA2025

Building evidence to support burden of dex Georgia McCaughan Jacqui Jagger CNRU💙 et al. Thanks for invitation Maura Dowling Seminars in Oncology Nursing Rahul Banerjee, MD, FACP Beth Faiman PhD Monica Morris Development and Validation of a Patient-Reported Outcome Measure to As... sciencedirect.com/science/articl…

Fantastic to work with Tracy King developing and validating a Patient Reported Outcome Measure to assess the burden of steroid related symptoms in patients with multiple myeloma - congratulations Tracy! #mmsm

We’ll be using this SSQ-MM PRO measure in our upcoming “ICLEARDEX” trial of corticosteroid-sparing Isa-KRd - excited to see results. Congrats Tracy King Georgia McCaughan et al on excellent #downwithdex work! Cc Joseph Mikhael Vincent Rajkumar Beth Faiman PhD #MMsm authors.elsevier.com/a/1lMc72gMQS9q…

Now in big The Lancet - in vivo 🇨🇳 BCMA CAR in myeloma #MMsm! Off the shelf in a big way - clever design as ⬇️ including don’t-eat-me and CD47 knockdown. 4 pts who received this did well; most had Gr3 CRS. Circulating 🦠 out in 48 hours, peak 🚗 at D10-17. Exciting to see!

Just in time for ODAC, DREAMM-7 OS with belantamab in The Lancet Oncology by VaniaHungria et al. Look at those survival curves! They estimate mOS of 7 years (!) with Bela-Vd based on modeling even in R/R myeloma #MMsm. No T-cell collection, no CRS risk - great for pts around 🌍!

We have advertised our myeloma fellow job at St Vincent’s for 2026. If you are interested in plasma cell dyscrasias, being involved in clinical trials and/or translational research Garvan Institute of Medical Research Phan Lab - please reach out! jobs.health.nsw.gov.au/JMO-ex/jobs/pr…

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…

1/ Our call to action is out in Blood Advances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.

Kidney transplantation in PCDs is now a real option for select patients with ESKD due to MM, AL amyloidosis, or MGRS. A multidisciplinary panel reviews evolving evidence, challenges, and opportunities in this life-changing therapy. BU Amyloidosis Center kidney-international.org/article/S0085-…

1/ Legend* has it that one can predict bsAb efficacy in #MMsm after a single dose… * No longer a legend! Cool Journal of Clinical Investigation piece by Duffy Madhav Dhodapkar Sagar Lonial MD et al showing ∆ outcomes in myeloma based on CD4 T-cell profiling only 24-48 hrs after 1st tec dose.